Compare DMRA & BLKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRA | BLKB |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2020 | 2004 |
| Metric | DMRA | BLKB |
|---|---|---|
| Price | $22.10 | $52.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $46.78 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 478.7K | 389.9K |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 121.48 | ★ 142.32 |
| EPS | N/A | ★ 2.49 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.30 |
| Revenue Next Year | N/A | $4.68 |
| P/E Ratio | ★ N/A | $21.66 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.50 | $25.58 |
| 52 Week High | $34.89 | $64.84 |
| Indicator | DMRA | BLKB |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 49.67 |
| Support Level | $18.03 | $45.71 |
| Resistance Level | $22.27 | $53.25 |
| Average True Range (ATR) | 1.83 | 1.70 |
| MACD | 0.03 | -0.54 |
| Stochastic Oscillator | 30.13 | 17.31 |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.